Key facts
- Nektar Therapeutics granted stock options on May 20, 2026.
- The options are for 11,900 shares of common stock.
- The grants were made under Nasdaq Listing Rule 5635(c)(4).
Nektar Therapeutics (NASDAQ: NKTR) announced on June 3, 2026, that its Organization and Compensation Committee granted non-qualified stock options on May 20, 2026. These options allow for the purchase of an aggregate of 11,900 shares of the company's common stock. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).